EGFR and urinary bladder cancer: To study antitumor efficacy of the 111In delivered by EGFR-targeted MNT on human bladder cancer xenografts, 9.2 MBq (4 μg) of 111In-NOTA-DTox-HMP-NLS-EGF, 9.2 MBq of 111In without MNT, 4 μg NOTA-DTox-HMP-NLS-EGF without 111In, or saline were intratumorally injected into subcutaneous EJ xenografts on the 14th day after establishing the EJ tumor.